BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29345515)

  • 1. Safety of biologic agents for psoriasis in patients with viral hepatitis.
    AlMutairi N; Abouzaid HA
    J Dermatolog Treat; 2018 Sep; 29(6):553-556. PubMed ID: 29345515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
    Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
    Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.
    Sanz-Bueno J; Vanaclocha F; García-Doval I; Torrado R; Carretero G; Daudén E; Patricia Ruiz-Genao D; Alsina-Gibert MM; Pérez-Zafrilla B; Pérez-Rial G; Rivera R;
    Actas Dermosifiliogr; 2015; 106(6):477-82. PubMed ID: 25776200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.
    Chiu HY; Chen CH; Wu MS; Cheng YP; Tsai TF
    Br J Dermatol; 2013 Dec; 169(6):1295-303. PubMed ID: 23746170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
    Piaserico S; Messina F; Russo FP
    Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
    Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
    Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
    Bonifati C; Lora V; Graceffa D; Nosotti L
    World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
    Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.
    Ting SW; Chen YC; Huang YH
    Clin Drug Investig; 2018 Sep; 38(9):873-880. PubMed ID: 29968197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
    Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
    J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study.
    Chiu HY; Chiu YM; Chang Liao NF; Chi CC; Tsai TF; Hsieh CY; Hsieh TY; Lai KL; Chiu TM; Wu NL; Hui RC; Lee CN; Wang TS; Chen PH; Yang CC; Huang YH
    J Am Acad Dermatol; 2021 Aug; 85(2):337-344. PubMed ID: 31821860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
    Saitta C; Pontisso P; Brunetto MR; Fargion S; Gaeta GB; Niro GA; Picciotto A; Smedile A; Squadrito G; Raimondo G
    Antivir Ther; 2006; 11(7):931-4. PubMed ID: 17302256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.
    Snast I; Atzmony L; Braun M; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Jul; 77(1):88-97.e5. PubMed ID: 28495497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Features of combined (HBV/HCV-infection) viral lesion of the liver].
    Maev IV; Nikushkina IN; Samsonov AA; Aksel'rod AG
    Ter Arkh; 2008; 80(2):57-61. PubMed ID: 18372598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
    Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
    J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological pattern in plasma, peripheral blood mononuclear cells and liver tissue and clinical outcome in chronic hepatitis B and C virus coinfection.
    Coppola N; Pisapia R; Tonziello G; Martini S; Imparato M; Piai G; Stanzione M; Sagnelli C; Filippini P; Piccinino F; Sagnelli E
    Antivir Ther; 2008; 13(2):307-18. PubMed ID: 18505182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.
    Preda CM; Popescu CP; Baicus C; Constantinescu I; Oproiu A; Voiosu T; Diculescu M; Negreanu L; Gheorghe L; Sporea I; Trifan A; Ceausu E; Proca D; Manuc M
    J Viral Hepat; 2018 Jul; 25(7):834-841. PubMed ID: 29397016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre.
    Giannousis IP; Papatheodoridis GV; Deutsch MJ; Manolakopoulos SG; Manesis EK; Koskinas JS; Archimandritis AJ
    Eur J Gastroenterol Hepatol; 2010 Feb; 22(2):172-9. PubMed ID: 19738477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.